This hypothesis is supported by the clinical and preclinical findings that scopolamine, a non-selective muscarinic acetylcholine receptor antagonist, reverses depression-like behaviors or symptoms in an established animal model or in human patients41,42, and shRNA-mediated knockdown of acetylcholinesterase in mouse hippocampus induces the symptoms of depression6. This evidence concerns the gene ACHE and depressive disorder.